183 related articles for article (PubMed ID: 38536842)
1. GraphMHC: Neoantigen prediction model applying the graph neural network to molecular structure.
Jeong H; Cho YR; Gim J; Cha SK; Kim M; Kang DR
PLoS One; 2024; 19(3):e0291223. PubMed ID: 38536842
[TBL] [Abstract][Full Text] [Related]
2. High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets.
Shao XM; Bhattacharya R; Huang J; Sivakumar IKA; Tokheim C; Zheng L; Hirsch D; Kaminow B; Omdahl A; Bonsack M; Riemer AB; Velculescu VE; Anagnostou V; Pagel KA; Karchin R
Cancer Immunol Res; 2020 Mar; 8(3):396-408. PubMed ID: 31871119
[TBL] [Abstract][Full Text] [Related]
3. IConMHC: a deep learning convolutional neural network model to predict peptide and MHC-I binding affinity.
Pei B; Hsu YH
Immunogenetics; 2020 Jul; 72(5):295-304. PubMed ID: 32577798
[TBL] [Abstract][Full Text] [Related]
4. Improvement of Neoantigen Identification Through Convolution Neural Network.
Hao Q; Wei P; Shu Y; Zhang YG; Xu H; Zhao JN
Front Immunol; 2021; 12():682103. PubMed ID: 34113354
[TBL] [Abstract][Full Text] [Related]
5. pTuneos: prioritizing tumor neoantigens from next-generation sequencing data.
Zhou C; Wei Z; Zhang Z; Zhang B; Zhu C; Chen K; Chuai G; Qu S; Xie L; Gao Y; Liu Q
Genome Med; 2019 Oct; 11(1):67. PubMed ID: 31666118
[TBL] [Abstract][Full Text] [Related]
6. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
Barajas A; Amengual-Rigo P; Pons-Grífols A; Ortiz R; Gracia Carmona O; Urrea V; de la Iglesia N; Blanco-Heredia J; Anjos-Souza C; Varela I; Trinité B; Tarrés-Freixas F; Rovirosa C; Lepore R; Vázquez M; de Mattos-Arruda L; Valencia A; Clotet B; Aguilar-Gurrieri C; Guallar V; Carrillo J; Blanco J
J Transl Med; 2024 Jan; 22(1):14. PubMed ID: 38172991
[TBL] [Abstract][Full Text] [Related]
7. DeepHLApan: A Deep Learning Approach for Neoantigen Prediction Considering Both HLA-Peptide Binding and Immunogenicity.
Wu J; Wang W; Zhang J; Zhou B; Zhao W; Su Z; Gu X; Wu J; Zhou Z; Chen S
Front Immunol; 2019; 10():2559. PubMed ID: 31736974
[TBL] [Abstract][Full Text] [Related]
8. Graph-pMHC: graph neural network approach to MHC class II peptide presentation and antibody immunogenicity.
Thrift WJ; Perera J; Cohen S; Lounsbury NW; Gurung HR; Rose CM; Chen J; Jhunjhunwala S; Liu K
Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38555476
[TBL] [Abstract][Full Text] [Related]
9. Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information.
Kim S; Kim HS; Kim E; Lee MG; Shin EC; Paik S; Kim S
Ann Oncol; 2018 Apr; 29(4):1030-1036. PubMed ID: 29360924
[TBL] [Abstract][Full Text] [Related]
10. NeoScore Integrates Characteristics of the Neoantigen:MHC Class I Interaction and Expression to Accurately Prioritize Immunogenic Neoantigens.
Borden ES; Ghafoor S; Buetow KH; LaFleur BJ; Wilson MA; Hastings KT
J Immunol; 2022 Apr; 208(7):1813-1827. PubMed ID: 35304420
[TBL] [Abstract][Full Text] [Related]
11. Neo-intline: integrated pipeline enables neoantigen design through the in-silico presentation of T-cell epitope.
Li B; Jing P; Zheng G; Pi C; Zhang L; Yin Z; Xu L; Qiu J; Gu H; Qiu T; Fang J
Signal Transduct Target Ther; 2023 Oct; 8(1):397. PubMed ID: 37848417
[TBL] [Abstract][Full Text] [Related]
12. Precision Neoantigen Discovery Using Large-scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation.
Pyke RM; Mellacheruvu D; Dea S; Abbott CW; Zhang SV; Phillips NA; Harris J; Bartha G; Desai S; McClory R; West J; Snyder MP; Chen R; Boyle SM
Mol Cell Proteomics; 2021; 20():100111. PubMed ID: 34126241
[TBL] [Abstract][Full Text] [Related]
13. Deep convolutional neural networks for pan-specific peptide-MHC class I binding prediction.
Han Y; Kim D
BMC Bioinformatics; 2017 Dec; 18(1):585. PubMed ID: 29281985
[TBL] [Abstract][Full Text] [Related]
14. A multimodal graph neural network framework for cancer molecular subtype classification.
Li B; Nabavi S
BMC Bioinformatics; 2024 Jan; 25(1):27. PubMed ID: 38225583
[TBL] [Abstract][Full Text] [Related]
15. Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
Bai P; Li Y; Zhou Q; Xia J; Wei PC; Deng H; Wu M; Chan SK; Kappler JW; Zhou Y; Tran E; Marrack P; Yin L
Oncoimmunology; 2021 Jan; 10(1):1868130. PubMed ID: 33537173
[TBL] [Abstract][Full Text] [Related]
16. Prioritizing candidate peptides for cancer vaccines through predicting peptide presentation by HLA-I proteins.
Zhou LY; Zou F; Sun W
Biometrics; 2023 Sep; 79(3):2664-2676. PubMed ID: 35833513
[TBL] [Abstract][Full Text] [Related]
17. Ab-initio conformational epitope structure prediction using genetic algorithm and SVM for vaccine design.
Moghram BA; Nabil E; Badr A
Comput Methods Programs Biomed; 2018 Jan; 153():161-170. PubMed ID: 29157448
[TBL] [Abstract][Full Text] [Related]
18. Neodb: a comprehensive neoantigen database and discovery platform for cancer immunotherapy.
Wu T; Chen J; Diao K; Wang G; Wang J; Yao H; Liu XS
Database (Oxford); 2023 Jun; 2023():. PubMed ID: 37311149
[TBL] [Abstract][Full Text] [Related]
19. Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade.
Richman LP; Vonderheide RH; Rech AJ
Cell Syst; 2019 Oct; 9(4):375-382.e4. PubMed ID: 31606370
[TBL] [Abstract][Full Text] [Related]
20. CapsNet-MHC predicts peptide-MHC class I binding based on capsule neural networks.
Kalemati M; Darvishi S; Koohi S
Commun Biol; 2023 May; 6(1):492. PubMed ID: 37147498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
